Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Pfister

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Bioorganic & Medicinal Chemistry Letters|January 14, 2020
Discovery and optimization of novel pyridines as highly potent and selective glycogen synthase kinase 3 inhibitorsSavithri Ramurthy, Keith B Pfister, Rustum S Boyce, et al.
Ophthalmology and Therapy|February 3, 2026
One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network ReportGabriela Grimaldi, Nicolò Bartolomeo, Justus G Garweg, et al.
Ophthalmology and Therapy|October 17, 2025
One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network ReportAnne Tillmann, Richard Stillenmunkes, Justus G Garweg, et al.
Ophthalmology Science|March 5, 2026
Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network ReportJan Spindler, Dmitri Artemiev, Isabel B Pfister, et al.
Ophthalmology. Retina|March 26, 2025
One-Year Outcomes after Switching to Faricimab in Eyes with Pretreated Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network ReportGabriela Grimaldi, Aude Ambresin, Isabel B Pfister, et al.
Msphere|July 7, 2021
Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139Mohammad Kamruzzaman, Meagan Kelly, Richelle C Charles, et al.
Journal of Medicinal Chemistry|October 11, 2017
Synthesis, Binding Mode, and Antihyperglycemic Activity of Potent and Selective (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine Inhibitors of Glycogen Synthase Kinase 3Allan S Wagman, Rustum S Boyce, Sean P Brown, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Bioorganic & Medicinal Chemistry Letters|January 14, 2020
Discovery and optimization of novel pyridines as highly potent and selective glycogen synthase kinase 3 inhibitorsSavithri Ramurthy, Keith B Pfister, Rustum S Boyce, et al.
Ophthalmology and Therapy|February 3, 2026
One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network ReportGabriela Grimaldi, Nicolò Bartolomeo, Justus G Garweg, et al.
Ophthalmology and Therapy|October 17, 2025
One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network ReportAnne Tillmann, Richard Stillenmunkes, Justus G Garweg, et al.
Ophthalmology Science|March 5, 2026
Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network ReportJan Spindler, Dmitri Artemiev, Isabel B Pfister, et al.
Ophthalmology. Retina|March 26, 2025
One-Year Outcomes after Switching to Faricimab in Eyes with Pretreated Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network ReportGabriela Grimaldi, Aude Ambresin, Isabel B Pfister, et al.
Msphere|July 7, 2021
Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139Mohammad Kamruzzaman, Meagan Kelly, Richelle C Charles, et al.
Journal of Medicinal Chemistry|October 11, 2017
Synthesis, Binding Mode, and Antihyperglycemic Activity of Potent and Selective (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine Inhibitors of Glycogen Synthase Kinase 3Allan S Wagman, Rustum S Boyce, Sean P Brown, et al.
Pageof 7